USE OF AUTOLOGOUS EFFECTOR CELLS AND ANTIBODIES FOR TREATMENT OF MULTIPLE MYELOMA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Oct 30, 2009
filing date -
Oct 30, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present disclosure provides methods for treating multiple myeloma using a combination of autologous expanded and activated NK cells from the patient and an antibody that targets an antigen on myeloma cells and/or an antibody that targets the KIR antigen on NK cells, wherein the antibodies elicit ADCC toward myeloma cells. The present disclosure provides methods for treating multiple myeloma using a combination of autologous NK cells and the anti-CS1 antibody elotuzumab.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully